Thromboembolic disease after total hip arthroplasty: Who is at risk?

Clinical Orthopaedics and Related Research

Volumn 453, Issue , 2006, Pages 211-224

  Beksaç, Burak ^a,b   Valle, Alejandro González Della ^a,b   Salvati, Eduardo A ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBIN III; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; BONE CEMENT; CHEMOKINE; CYTOKINE; ESTROGEN; FIBRINOGEN; INTERLEUKIN 1; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

AGING; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN III DEFICIENCY; ATHEROSCLEROSIS; BLOOD CLOTTING; COMPRESSION THERAPY; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DISEASE PREDISPOSITION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; IMMOBILIZATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SOCIETY; MORBID OBESITY; PNEUMATIC TOOL; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; RISK FACTOR; SMOKING; STROKE; SURGICAL RISK; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; VARICOSIS; VENOUS THROMBOEMBOLISM; HIP ARTHROPLASTY; REVIEW; THROMBOEMBOLISM;

ARTHROPLASTY, REPLACEMENT, HIP; HUMANS; RISK FACTORS; THROMBOEMBOLISM;

EID: 33845398913     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000238848.41670.41     Document Type: Conference Paper

References (159)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT Study. Arch Intern Med. 1991;151:933-938.
2. Bae H, Westrich GH, Sculco TP, Salvati EA, Reich LM. The effect of preoperative donation of autologous blood on deep-vein thrombosis after total hip arthroplasty. J Bone Joint Surg Br. 2001;83:676-679.
3. Bertina RM. The prothrombin 20210 G to A variation and thrombosis. Curr Opin Hematol. 1998;5:339-342.
4. Bertina RM. Molecular risk factors for thrombosis. Thromb Haemost. 1999;82:601-609.
5. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
6. Bertina RM, Rosendaal FR. Venous thrombosis - the interaction of genes and environment. N Engl J Med. 1998;338:1840-1841.
7. Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003;349:109-111.
8. Binns M, Pho R. Femoral vein occlusion during hip arthroplasty. Clin Orthop Relat Res. 1990;255:168-172.
9. Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med. 1983;309:340-344.
10. Buehler KO, D'Lima DD, Petersilge WJ, Colwell CW Jr, Walker RH. Late deep venous thrombosis and delayed weightbearing after total hip arthroplasty. Clin Orthop Relat Res. 1999;361:123-130.
11. Butt AJ, McCarthy T, Kelly IP, Glynn T, McCoy G. Sciatic nerve palsy secondary to postoperative haematoma in primary total hip replacement. J Bone Joint Surg Br. 2005;87:1465-1467.
12. Callaghan JJ, Dorr LD, Engh GA, Hanssen AD, Healy WL, Lachiewicz PF, Lonner JH, Lotke PA, Ranawat CS, Ritter MA, Salvati EA, Sculco TP, Thornhill TS. Prophylaxis for thromboembolic disease. J Arthroplasty. 2005;20:273-274.
13. Choudhury A, Lip GY. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol Haemost Thromb. 2003;33:282-289.
14. Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index: a reliability study. Int Disabil Stud. 1988;10:61-63.
15. Colwell CW Jr, Berkowitz SD, Lieberman JR, Comp PC, Ginsberg JS, Paiement G, McElhattan J, Roth AW, Francis CW. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005;87:2169-2177.
16. Cosman F, Baz-Hecht M, Cushman M, Vardy MD, Cruz JD, Nieves JW, Zion M, Lindsay R. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res. 2005;116:1-13.
17. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281:2189-2197.
18. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004-1008.
19. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions: The Cerebral Venous Sinus Thrombosis Study Group. BMJ. 1998;316:589-592.
20. De Stefano V, Zappacosta B, Persichilli S, Rossi E, Casorelli I, Paciaroni K, Chiusolo P, Leone AM, Giardina B, Leone G. Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. Br J Haematol. 1999;106:564-568.
21. Dearborn JT, Harris WH. Postoperative mortality after total hip arthroplasty: an analysis of deaths after two thousand seven hundred and thirty-six procedures. J Bone Joint Surg Am. 1998;80:1291-1294.
22. Della Valle CJ, Issack PS, Baitner A, Steiger DJ, Fang C, Di Cesare PE. The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty. BMC Musculoskelet Disord. 2001;2:1-6.
23. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
24. DiGiovanni CW, Restrepo A, Gonzalez Della Valle AG, Sharrock NE, McCabe JP, Sculco TP, Pellicci PM, Salvati EA. The safety and efficacy of intraoperative heparin in total hip arthroplasty. Clin Orthop Relat Res. 2000;379:178-185.
25. Dinckal MH, Davutoglu V, Soydinc S, Akdemir I, Aksoy M. Large thrombus at the site of primary sutured atrial septal defect associated with pulmonary embolism and treatment by thrombolysis. Echocardiography. 2003;20:535-538.
26. Dripps RD. New classification of physical status. Anesthesiology. 1963;24:111-115.
27. Edmonds MJ, Crichton TJ, Runciman WB, Pradhan M. Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J Surg. 2004;74:1082-1097.
28. Egeberg O. Inherited Antithrombin Deficiency Causing Thrombophilia. Thromb Diath Haemorrh. 1965;13:516-530.
29. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995;56:142-150.
30. Eriksson BI, Lassen MR. PENTasaccharide in HIp-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003;163:1337-1342.
31. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb. 1994;14:1080-1083.
32. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
33. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham D, Bryant J, Dimitrov N, Abramson N, Atkins J, Shibata H, Deschenes L, Margolese R. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor- positive breast cancer. J Natl Cancer Inst. 1997;89:1673-1682.
34. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet. 2001;109:369-384.
35. Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000;82:929-938.
36. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
37. Gale AJ, Gordon SG. Update on tumor cell procoagulant factors. Acta Haematol. 2001;106:25-32.
38. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338S-400S.
39. Gitel SN, Salvati EA, Wessler S, Robinson HJ Jr, Worth MH Jr. The effect of total hip replacement and general surgery on antithrombin III in relation to venous thrombosis. J Bone Joint Surg Am. 1979;61:653-656.
40. Glueck CJ, Bell H, Vadlamani L, Gupta A, Fontaine RN, Wang P, Stroop D, Gruppo R. Heritable thrombophilia and hypofibrinolysis: possible causes of retinal vein occlusion. Arch Ophthalmol. 1999;117:43-49.
41. Glueck CJ, Fontaine RN, Gruppo R, Stroop D, Sieve-Smith L, Tracy T, Wang P. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop Relat Res. 1999;366:133-146.
42. Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Weksler BB, Eldor A. Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol. 2001;97:44-48.
43. Glueck CJ, McMahon RE, Bouquot JE, Triplett D. Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain. Cranio. 1998;16:143-153.
44. Glueck CJ, McMahon RE, Bouquot JE, Triplett D, Gruppo R, Wang P. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. J Lab Clin Med. 1997;130:540-543.
45. Glueck CJ, Pranikoff J, Aregawi D, Haque M, Zhu B, Tracy T, Wang P. The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage. Metabolism. 2005;54:1345-1349.
46. Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Lang JE. Interaction of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: a cross-sectional study of 275 hyperlipidemic women. Metabolism. 2001;50:360-365.
47. Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost. 2004;10:323-334.
48. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277:642-645.
49. Goldhaber SZ, Savage DD, Garrison RJ, Castelli WP, Kannel WB, McNamara PM, Gherardi G, Feinleib M. Risk factors for pulmonary embolism: The Framingham Study. Am J Med. 1983;74:1023-1028.
50. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164:1965-1976.
51. Gonzalez Della Valle A, Comba F, Salvati EA. Favorable mid term results of the VerSys CT polished cemented femoral stem for total hip arthroplasty. Int Orthop. 2006 Mar 31;[Epub ahead of print].
52. Gonzalez Della Valle A, Serota A, Sorriaux G, Go G, Sharrock N, Sculco TP, Salvati E. Venous thromboembolism is rare after total hip arthroplasty with a multimodal prophylaxis protocol. Clin Orthop Relat Res. 2006;443:146-153.
53. Gonzalez-Ordonez AJ, Fernandez-Carreira JM, Fernandez-Alvarez CR, Venta Obaya R, Macias-Robles MD, Gonzalez-Franco A, Arias Garcia MA. The concentrations of soluble vascular cell adhesion molecule-1 and lipids are independently associated with venous thromboembolism. Haematologica. 2003;88:1035-1043.
54. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S, for the Heart and Estrogen/progestin Replacement Study Research Group. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689-696.
55. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370-1373.
56. Haas S. Deep vein thrombosis: beyond the operating table. Orthopedics. 2000;23:s629-s632.
57. Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. Blood Rev. 2005;19:179-202.
58. Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "the study of men born in 1913". Arch Intern Med. 1999;159:1886-1890.
59. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769-774.
60. Hefley FG Jr, Nelson CL, Puskarich-May CL. Effect of delayed admission to the hospital on the preoperative prevalence of deep-vein thrombosis associated with fractures about the hip. J Bone Joint Surg Am. 1996;78:581-583.
61. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512-1516.
62. Heit JA. Cancer and venous thromboembolism: scope of the problem. Cancer Control. 2005;12(Suppl 1):5-10.
63. rd. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245-1248.
64. rd. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452-463.
65. rd. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159:445-453.
66. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.
67. Hitos K, Fletcher JP. Venous thromboembolism and fractured neck of femur. Thromb Haemost. 2005;94:991-996.
68. Hooker JA, Lachiewicz PF, Kelley SS. Efficacy of prophylaxis against thromboembolism with intermittent pneumatic compression after primary and revision total hip arthroplasty. J Bone Joint Surg Am. 1999;81:690-696.
69. Hundsdoerfer P, Vetter B, Stover B, Bassir C, Scholz T, Grimmer I, Monch E, Ziemer S, Rossi R, Kulozik AE. Homozygous and double heterozygous Factor V Leiden and Factor II G20210A genotypes predispose infants to thromboembolism but are not associated with an increase of foetal loss. Thromb Haemost. 2003;90:628-635.
70. Hung J, Landzberg MJ, Jenkins KJ, King ME, Lock JE, Palacios IF, Lang P. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol. 2000;35:1311-1316.
71. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA. 1994;271:1780-1785.
72. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J. 1993;14:205-212.
73. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988;43:414-421.
74. Karavidas A, Lazaros G, Matsakas E, Kouvousis N, Samara C, Christoforatou E, Zacharoulis A. Early pacemaker lead thrombosis leading to massive pulmonary embolism. Echocardiography. 2004;21:429-432.
75. Kelly J, Rudd A, Lewis RR, Coshall C, Moody A, Hunt BJ. Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. Stroke. 2004;35:2320-2325.
76. Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756-2761.
77. Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med. 2002;126:1326-1336.
78. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589-1596.
79. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9-13.
80. Lachiewicz PF, Kelley SS, Haden LR. Two mechanical devices for prophylaxis of thromboembolism after total knee arthroplasty: a prospective, randomised study. J Bone Joint Surg Br. 2004;86:1137-1141.
81. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95:1517-1532.
82. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
83. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752-763.
84. Lieberman JR. Venous thromboembolism after total hip arthroplasty. In: Callaghan JJ, Rosenberg AG, Rubash HE, eds. The Adult Hip, Vol 1. Philadelphia: Lippincott-Raven; 1998:633-646.
85. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol. 1999;33:1424-1426.
86. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251-257.
87. Lotke PA, Palevsky H, Keenan AM, Meranze S, Steinberg ME, Ecker ML, Kelley MA. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Relat Res. 1996;324:251-258.
88. Lowe GD, Haverkate F, Thompson SG, Turner RM, Bertina RM, Turpie AG, Mannucci PM. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study: European Concerted Action on Thrombosis. Thromb Haemost. 1999;81:879-886.
89. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation. 1996;93:106-110.
90. Macaulay W, Westrich G, Sharrock N, Sculco TP, Jhon PH, Peterson MG, Salvati EA. Effect of pneumatic compression on fibrinolysis after total hip arthroplasty. Clin Orthop Relat Res. 2002;399:168-176.
91. Makris M. Hyperhomocysteinemia and thrombosis. Clin Lab Haematol. 2000;22:133-143.
92. Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL. Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. Anesthesiology. 2002;96:1140-1146.
93. Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology. 2003;99:552-560. discussion 555A
94. Markel DC, Urquhart B, Derkowska I, Salvati EA, Sharrock NE. Effect of epidural analgesia on venous blood flow after hip arthroplasty. Clin Orthop Relat Res. 1997;334:168-174.
95. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombingene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793-1797.
96. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997;77:444-451.
97. Merkel D, Zippel C, Rech P. Low molecular weight heparins after orthopedic and traumatologic operations in geriatrics. Z Gerontol Geriatr. 2002;35:54-59.
98. Mont MA, Jones LC, Rajadhyaksha AD, Shuler MS, Hungerford DS, Sieve-Smith L, Wang P, Cordista AG, Glueck CJ. Risk factors for pulmonary emboli after total hip or knee arthroplasty. Clin Orthop Relat Res. 2004;422:154-163.
99. Movahed MR, Hashemzadeh M, Jamal MM. The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. Chest. 2005;128:3568-3571.
100. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost. 2002;88:407-414.
101. Nassif JM, Ritter MA, Meding JB, Keating EM, Faris PM. The effect of intraoperative intravenous fixed-dose heparin during total joint arthroplasty on the incidence of fatal pulmonary emboli. J Arthroplasty. 2000;15:16-21.
102. Nizankowska-Mogilnicka E, Adamek L, Grzanka P, Domagala TB, Sanak M, Krzanowski M, Szczeklik A. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. Eur Respir J. 2003;21:25-30.
103. Parkin L, Skegg DC, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet. 2000;355:2133-2134.
104. Pellegrini VD Jr, Clement D, Lush-Ehmann C, Keller GS, Evarts CM. The John Charnley Award: natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res. 1996;333:27-40.
105. Pellegrini VD Jr, Donaldson CT, Farber DC, Lehman EB, Evarts CM. The John Charnley Award: prevention of readmission for venous thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res. 2005;441:56-62.
106. Pitto RP, Koessler M, Draenert K. The John Charnley Award: Prophylaxis of fat and bone marrow embolism in cemented total hip arthroplasty. Clin Orthop Relat Res. 1998;355:23-34.
107. Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N, Beau B. Prevention of deep vein thrombosis after hip replacement - comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999;81:22-25.
108. Planes A, Vochelle N, Fagola M. Total hip replacement and deep vein thrombosis: a venographic and necropsy study. J Bone Joint Surg Br. 1990;72:9-13.
109. Pola E, Flex A, Papaleo P, Gaetani E, Delcogliano A, Pola P. Deep venous thrombosis and pulmonary embolism after knee arthroscopy in athletes carrying the thrombophilic factor lupus anticoagulant. Arthroscopy. 2005;21:103-107.
110. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
111. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, Prins MH, Girolami A. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348:1435-1441.
112. Prandoni P, Lensing AW, Prins MH, Frulla M, Marchiori A, Bernardi E, Tormene D, Mosena L, Pagnan A, Girolami A. Belowknee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med. 2004;141:249-256.
113. Prevention. Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA. 1986;256:744-749.
114. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999;82:610-619.
115. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22:201-210.
116. Ruiz-Quezada S, Vazquez-Del Mercado M, Parra-Rojas I, Rangel-Villalobos H, Best-Aguilera C, Sanchez-Orozco LV, Munoz-Valle JF. Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico: association with biochemical and hematological parameters. Ann Genet. 2004;47:155-162.
117. Ryan DH, Crowther MA, Ginsberg JS, Francis CW. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med. 1998;128:270-276.
118. Ryan MG, Westrich GH, Potter HG, Sharrock N, Maun LM, Macaulay W, Katkin P, Sculco TP, Salvati EA. Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography. J Bone Joint Surg Am. 2002;84:1998-2004.
119. Sainsbury A, Seebass G, Bansal A, Young JB. Reliability of the Barthel Index when used with older people. Age Ageing. 2005;34:228-232.
120. Salvati EA, Gonzalez Della Valle A. Thromboembolism following total hip replacement. J Long Term Eff Med Implants. 2003;13:325-340.
121. Salvati EA, Gonzalez Della Valle A, Westrich GH, Rana AJ, Specht L, Weksler BB, Wang P, Glueck CJ. The John Charnley Award: heritable thrombophilia and development of thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res. 2005;441:40-55.
122. Salvati EA, Sharrock NE, Gonzalez Della Valle A. Current concepts in in the pathogenesis, diagnosis and multimodal prophylaxis of thromboembolism disease following total hip replacement. Minerva Ortopedica e Traumatologica. 2003;54:381-401.
123. Sarmiento A, Goswami AD. Thromboembolic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty. J Bone Joint Surg Am. 1999;81:339-346.
124. Shaieb MD, Watson BN, Atkinson RE. Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis. J Arthroplasty. 1999;14:432-438.
125. Sharrock NE, Brien WW, Salvati EA, Mineo R, Garvin K, Sculco TP. The effect of intravenous fixed-dose heparin during total hip arthroplasty on the incidence of deep-vein thrombosis: a randomized, double-blind trial in patients operated on with epidural anesthesia and controlled hypotension. J Bone Joint Surg Am. 1990;72:1456-1461.
126. Sharrock NE, Go G, Harpel PC, Ranawat CS, Sculco TP, Salvati EA. The John Charnley Award: thrombogenesis during total hip arthroplasty. Clin Orthop Relat Res. 1995;319:16-27.
127. Sharrock NE, Go G, Sculco TP, Salvati EA, Westrich GH, Harpel PC. Dose response of intravenous heparin on markers of thrombosis during primary total hip replacement. Anesthesiology. 1999;90:981-987.
128. Sharrock NE, Mineo R, Go G. The effect of cardiac output on intraoperative blood loss during total hip arthroplasty. Reg Anesth. 1993;18:24-29.
129. Sharrock NE, Mineo R, Urquhart B, Salvati EA. The effect of two levels of hypotension on intraoperative blood loss during total hip arthroplasty performed under lumbar epidural anesthesia. Anesth Analg. 1993;76:580-584.
130. Sharrock NE, Ranawat CS, Urquhart B, Peterson M. Factors influencing deep vein thrombosis following total hip arthroplasty under epidural anesthesia. Anesth Analg. 1993;76:765-771.
131. Sharrock NE, Salvati EA. Hypotensive epidural anesthesia for total hip arthroplasty: a review. Acta Orthop Scand. 1996;67:91-107.
132. Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, Benedetti L, Girolami A. Hyperhomocysteinemia and deep-vein thrombosis: a case-control study. Thromb Haemost. 1996;76:883-886.
133. Simmons AV, Sheppard MA, Cox AF. Deep venous thrombosis after myocardial infarction. Lancet. 1973;35:623-625.
134. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the anticoagulation in cardioversion using enoxaparin (ACE) trial. Circulation. 2004;109:997-1003.
135. Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, Conkie JA, Bertina RM. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995;73:87-93.
136. Tapson VF. The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:71-77.
137. The PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005;112:416-422.
138. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002;87:1076-1077.
139. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol. 1992;21:48-52.
140. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002;162:1182-1189.
141. van der Meer FJ, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost. 1997;78:631-635.
142. Varughese GI, Patel JV, Tomson J, Lip GYH. The prothrombotic risk of diabetes mellitus in atrial fibrillation and heart failure. J Thromb Haemost. 2005;3:2811-2813.
143. Virchow R. Neuer fall von todlicher emboli der lungenarterie. Arch Pathol Anat. 1856;10:225-228.
144. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - a meta-analysis. Lupus. 1997;6:467-473.
145. Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998;7:15-22.
146. Wahlander K, Larson G, Lindahl TL, Andersson C, Frison L, Gustafsson D, Bylock A, Eriksson BI. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thromb Haemost. 2002;87:580-585.
147. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:311S-337S.
148. Weill-Engerer S, Meaume S, Lahlou A, Piette F, Saint-Jean O, Sachet A, Beinis J-Y, Gallinari C, Grancher A-S, Vincent J-P, Naga H, Belmin J, Salvatore R, Kazes M, Pautas E, Boiffin A, Piera J-B, Duviquet M, Knafo D, Piau A, Miric D, Jean A, Bellamy V, Tissandier O. Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc. 2004;52:1299-1304.
149. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64:169-172.
150. Westrich GH, Farrell C, Bono JV, Ranawat CS, Salvati EA, Sculco TP. The incidence of venous thromboembolism after total hip arthroplasty: a specific hypotensive epidural anesthesia protocol. J Arthroplasty. 1999;14:456-463.
151. Westrich GH, Sanchez PM. Prevention and treatment of thromboembolic disease: an overview. Instr Course Lect. 2002;51:471-480.
152. Westrich GH, Specht LM, Sharrock NE, Sculco TP, Salvati EA, Pellicci PM, Trombley JF, Peterson M. Pneumatic compression hemodynamics in total hip arthroplasty. Clin Orthop Relat Res. 2000;372:180-191.
153. White RH, Gettner S, Newman JM, Trauner KB, Romano PS. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med. 2000;343:1758-1764.
154. White RH, Zhou H, Gage BF. Effect of age on the incidence of venous thromboembolism after major surgery. J Thromb Haemost. 2004;2:1327-1333.
155. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90:446-455.
156. Woolson ST, Zehnder JL, Maloney WJ. Factor V Leiden and the risk of proximal venous thrombosis after total hip arthroplasty. J Arthroplasty. 1998;13:207-210.
157. Zahn HR, Skinner JA, Porteous MJ. The preoperative prevalence of deep vein thrombosis in patients with femoral neck fractures and delayed operation. Injury. 1999;30:605-607.
158. Zoller B, Garcia de Frutos P, Hillarp A, Dahlback B. Thrombophilia as a multigenic disease. Haematologica. 1999;84:59-70.
159. Nathan SS, Simmons KH, Lin PP, Hann LE, Morris CD, Athanasian EA, Boland PJ, Healey JH. Proximal deep vein thrombosis after hip replacement for oncologic indications. J Bone Joint Surg Am. 2006;88:1066-1070.